Multidisciplinary approach in diagnostics and treatment of gastric cancer

Česká verzia

Authors: R. Obermannová ¹; J. Novák ^1,2; I. Novotný ³; L. Němec ⁴; R. Vyzula ¹
Authors place of work: Klinika komplexní onkologické péče, MOU, Brno ¹; Úsek národního onkologického registru, MOÚ, Brno ²; Gastroenterologická ambulance, MOÚ, Interní gastroenterologická klinika FN Brno ³; Chirurgické oddělení, MOÚ, Brno ⁴
Published in the journal: Gastroent Hepatol 2013; 67(5): 390-395
Category: Gastrointestinal Oncology: Review Article

Summary

The incidence of gastric cancer has been declining globally but mortality remains high. The only curative approach is surgery. Endoscopic mucosal resection can be used in early clinical stages. Only a multidisciplinary approach involving a surgeon, a gastroenterologist, and an oncologist can produce the comprehensive strategy in locally advanced gastric cancer. Gastrectomy with the lymph node dissection in combination with chemotherapy and radiotherapy prolongs overall survival. Palliative chemotherapy involving Fluoropyrimidine and Cisplatin is indicated in a metastatic setting. The addition of trastuzumab to chemotherapy is the standard of care in HER2-positive oesophageal and gastric adenocarcinomas and leads to an improved overall survival from 10 months to 13 months.

Key words:
gastric cancer – multimodal treatment – chemotherapy

Zdroje

1. SEER. SEER Stat Facts Sheets: Stomach Cancer [online]. Available from: http://www.seer.cancer.gov/statfacts/html/stomach.html.

2. Huntsman DG, Carneiro F, Lewis FR et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001; 344(25): 1904–1909.

3. Edgren G, Hjalgrim H, Rostgaard K et al. Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study. Am J Epidemiol 2010; 172(11): 1280–1285.

4. Wu CY, Wu MS, Kuo KN et al. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol 2010; 28(18): 2952–2957.

5. Correa P. Human gastric carcinogenesis: a multistep and multifactorial proces – first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res 1992; 52(24): 6735–6740.

6. Kumar RK, Raj SS, Shankar EM et al. Gastric carcinoma: a review on epidemiology, current surgical and chemotherapeutic options [online]. Available from: http://dx.doi.org/10.5772/45896.

7. Mezinárodní klasifikace nemocí pro onkologii: MKN-O-3 ČV. 3. vyd. Praha: Ústav zdravotnických informací a statistiky ČR 2004.

8. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC Press 2010.

9. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31–49.

10. TNM klasifikace zhoubných novotvarů. 7. vyd. Praha: Ústav zdravotnických informací a statistiky ČR 2011.

11. Edge SB, Byrd DR, Compton CC et al. AJCC cancer staging handbook. 7th ed. New York: Springer 2010.

12. Ajani JA, Bentrem DJ, Besh S et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2013; 11(5): 531–546.

13. Šimša J et al. Endoskopická léčba. In: Šimša J (eds). Karcinom žaludku. 1. vyd. Praha: Maxdorf 2012: 77–87.

14. Macdonald JS, Benedetti J, Smalley S et al. Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008) J Clin Oncol 2009; 27 (20 Suppl): 4515.

15. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355(1): 11–20.

16. Boige V, Pignon JP, Saint-Aubert et al. Final results of a randomized trial comparing preoperative 5-FU to surgery alone in adeno-carcinoma of the stomach and Loir esofagus: FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 2007; 25 (18 Suppl): 4510.

17. Van Cutsem E, Van de Velde C, Roth A et al. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) – gastrointestinal cancer group. Eur J Cancer 2008; 44(2): 182–194.

18. Bang YJ, Kim YW, Yang HK et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379(9813): 315–321.

19. Petera J, Dvořák J, Melichar B et al. Chemoradioterapie v neoadjuvantní léčbě karcinomu žaludku. Klin Onkol 2002; 15(6): 216–218.

20. ESMO Clinical Recommendations. Ann Oncol 2010.

21. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24(31): 4991–4997.

22. Okines AF, Norman AR, McCloud P et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009; 20(9): 1529–1534.

23. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376(9742): 687–697.

24. Ueda S, Hironaka S, Yasui H et al. Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of ﬂuoropyrimidine plus platinum (FP): WJOG4007 trial. J Clin Oncol 2012; 30 (Suppl): 4002.

25. Ford H, Marshall A, Wadsley J et al. A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. J Clin Oncol 2012; 30 (Suppl 34): LBA4.

26. Ajani JA, Rodriguez W, Bodoky G et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010; 28(9): 1547–1553.